Galiximab in Relapsed Hodgkin Lymphoma

Sonali M. Smith, MD Associate Professor Section of Hematology/Oncology Associate Director, Lymphoma Program The University of Chicago Medical Center Chicago, Illinois H&O What is the standard of […]

Update in T-cell Lymphoma

Owen A. O’Connor, MD, PhD Professor of Medicine and Pharmacology Deputy Cancer Center Director New York University Cancer Institute New York University Langone Medical Center New […]

First-line Treatment of Elderly Multiple Myeloma Patients

Antonio Palumbo, MD Associate Professor Torino University Torino, Italy H&O What is the standard of care for induction therapy in newly diagnosed myeloma patients older than 65 […]

New Agents in Early Clinical Trials for CLL Therapy

Richard R. Furman, MD Director CLL Research Center Weill Medical College New York, New York H&O What is the gold standard for chronic lymphocytic leukemia (CLL) therapy, […]

Update on Treatments for Patients With Myelodysplastic Syndrome

Guillermo Garcia-Manero, MD Associate Professor of Medicine Chief, Section of Myelodysplastic Syndromes Department of Leukemia University of Texas M.D. Anderson Cancer Center Houston, Texas H&O What is […]

Frontline Regimens for Multiple Myeloma Patients

Sagar Lonial, MD Associate Professor Department of Hematology and Medical Oncology Winship Cancer Institute Emory University School of Medicine Atlanta, Georgia H&O What is the standard of […]

Rituximab as Therapy for Acute Lymphoblastic Leukemia

Rituximab as Therapy for Acute Lymphoblastic Leukemia Deborah A. Thomas, MD, Associate Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas, M. D. Anderson Cancer Center, Houston, Texas H&O What […]

Updates on the Treatment of Acute Promyelocytic Leukemia

Updates on the Treatment of Acute Promyelocytic Leukemia Martin S. Tallman, MD, Professor of Medicine Associate Chief Division of Hematology/Oncology Feinberg School of Medicine Northwestern University Chicago, Illinois H&O What is the standard […]

Ofatumumab: A New Agent for Chronic Lymphocytic Leukemia

Ofatumumab: A New Agent for Chronic Lymphocytic Leukemia Anders Österborg, MD, PhD, Professor of Oncology, Karolinska University Hospital, Karolinska Institutet Stockholm, Sweden H&O How is ofatumumab different from other anti-CD20 antibodies such as […]

Imatinib: High Dose Versus Standard Dose

Imatinib: High Dose Versus Standard Dose Elias Jabbour, MD, Assistant Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas, M. D. Anderson Cancer Center, Houston, Texas H&O What do we […]

Update on Burkitt Lymphoma and Leukemia

Dieter Hoelzer, MD, PhD Professor of Medicine, Department of Hematology, University of Frankfurt, Frankfurt, Germany H&O Can you explain the different variants of Burkitt leukemia? DH Burkitt lymphoma […]